Kornimate/medical-research-clean huggingface dataset:
a integrated study in pediatric patients with cardiomyopathy

Conditions: Pediatric Cardiomyopathy

Summary: this observational study aims to manage children with cardiomyopathy in the long term. it collects baseline data, laboratory test data, and medical imaging data during the hospitalization and follow-up. during their disease progress, participants will undergo cardiovascular magnetic resonance, echocardiography, electrocardiography, laboratory tests, and when hospitalization and follow-up, and the baseline data will be collected in the admission. all the above examination data will be analysed to assess the clinical characteristics, current status of diagnosis and treatment, and the prognostic risk factors for children with cardiomyopathy.


Eligibility criteria:
inclusion criteria: * pediatric patients diagnosed with cardiomyopathy. exclusion criteria: * a history of cardiovascular disease ( such as congenital heart disease, cardiomyopathy, rheumatic heart disease, valvular disease ). * mentally abnormal. * poor compliance. * heart, kidney and other important organs were seriously incomplete.
effect of cross frequency tacs on cognitive control

Conditions: Cognitive Control; Executive Function

Summary: investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex

previous evidence suggests that there are specific frequency bands associated with different aspects of cognitive control. in specific delta (2-4hz) and beta (15-30hz) are associated with increased levels of abstraction for learned rules; and theta (5-8hz) and gamma (30-50hz) has been associated with increased set-size or number of learned rules. here we aim to find causal evidence in support of these previous correlational findings by applying cross-frequency transcranial alternating current stimulation (tacs) in the specific frequency bands previously shown to be task-relevant. in a crossover design, we stimulate subjects with either delta-beta or theta-gamma tacs during performance of a hierarchical cognitive control task that manipulates the level of abstraction and set-size of rules that must be learned in order to make the correct button press.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 35 years * able to provide informed consent * willing to comply with all study procedures and be available for the duration of the study speak and understand english exclusion criteria: * attention deficit hyperactivity disorder (currently under treatment) * neurological disorders and conditions, including, but not limited to: * history of epilepsy * seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) dementia * history of stroke * parkinson's disease * multiple sclerosis * cerebral aneurysm * brain tumors * medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy) * prior brain surgery * any brain devices/implants, including cochlear implants and aneurysm clips * history or current traumatic brain injury * (for females) pregnancy or breast feeding * personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.) * positive urine test for the following: marijuana (thc), cocaine (coc), phencyclidine (pcp), amphetamine (amp), ecstasy (mdma), methamphetamine (mamp), opiates (opi), oxycodone (oxy), methadone (mtd), barbiturates (bar), benzodiazepines (bzo), buprenorphine (bup), tricyclic antidepressants (tca), propoxyphene (ppx) * anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study

Keywords: tacs cognitive control executive function
ntrk gene fusion - positive advanced or recurrent solid tumors, a rare cancer caused by specific changes in the genes

Conditions: Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Summary: researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called trk fusion cancer. in people with trk fusion cancer, a gene called neurotrophic trk, (ntrk) joins or "fuses" with another gene. this creates a protein known as a fusion protein, which can cause cancer cells to grow. the study treatment, larotrectinib, is already available for doctors to prescribe to patients with trk fusion cancer. larotrectinib works by blocking trk genes in cancer cells which helps stop the cancer from growing. in this study, the researchers want to learn more about the safety and effectiveness of larotrectinib in adults and children with advanced or recurrent trk fusion cancer. this means that their cancer has spread from where it started to other areas of the body, or the cancer has come back after a period of time. to answer this question, the researchers will collect information from patients who are taking larotrectinib as prescribed by their doctors. the researchers will learn what adverse events the patients are having. an adverse event is any medical problem that a patient has during a study. doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. the study will include patients of all ages with trk fusion cancer. in this study, there will be no required tests or visits to a study site. instead, the researchers will collect information from: * the patients' medical records * interviews with the patients or their parents or guardians * the patients' visits to their doctor as part of their usual care the researchers will collect information about the adults for up to about 2 years and about the children for up to about 8 years.


Eligibility criteria:
inclusion criteria: * patients who are treated with larotrectinib or decided to be treated with larotrectinib, under routine clinical practice. exclusion criteria: * participation in an investigational program with interventions outside of routine clinical practice
efficacy and safety of sr58611a in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: to evaluate the efficacy of a fixed dose of sr58611a(350 mg q12) compared to placebo in patients with majordepressive disorder (mdd) using escitalopram (10 mgqd) as positive control. in addition, the tolerability and safety of sr58611a in patients with mdd will be evaluated.

to evaluate the efficacy of a fixed dose of sr58611a(350 mg q12) compared to placebo in patients with majordepressive disorder (mdd) using escitalopram (10 mgqd) as positive control. in addition, the tolerability and safety of sr58611a in patients with mdd will be evaluated. the present study is an 8-week, double-blind, placebo- and escitalopram-controlled, randomized, parallel-group study. a 1-week, placebo, single-blind period precedes the 8-week randomized treatment period and an optional 18-week, double-blind extension period follows the randomized treatment period. a safety follow up visit is scheduled 1 week after the acute and extension period, or early termination. escitalopram, a selective serotonin reuptake inhibitor (ssri), an approved treatment for mdd, is chosen as a positive control agent in this study. the dose of 10 mg is within the approved dose range with no need for dose adjustment in elderly patients. this trial is designed to formally compare the efficacy, safety, and tolerability of sr58611a to placebo. escitalopram is used as a positive control.

Eligibility criteria:
inclusion criteria: main inclusion criteria: * 1. out-patients, 18 year and older. * 2. major depressive disorder (mdd) with a recurrentmajor depressive episode (mde) according to dsmiv-tr criteria * 3. duration of current episode is at least of 6 weeksunless severity of symptoms justifies shorter duration. * 4. patients have been treated or hospitalized for aprevious episode, or a previous episode requiredantidepressant treatment(s) at the recommended doselevel for a continuous total duration of at least 2months. exclusion criteria: main exclusion criteria: * 1. patients at immediate risk for suicidal behavior * 2. patients with a mde with psychotic features, catatonic features, seasonal pattern or postpartum onset * 3. the duration of the current depressive episode is greater than 2 years * 4. patients whose current depressive episode is secondary to a general medical condition * 5. patients with a lifetime history of (1) bipolar disorder, (2) psychotic disorder, (3) antisocial personality disorder * 6. patients who have received non-pharmacologic, somatic treatments for psychiatric disease * 7. patients who have initiated, stopped, or changed the frequency or nature of psychotherapy within 3 months prior to screening

Keywords: major depressive disorder depression major depressive episode antidepressive agents
effect of citrulline on the clinical and biochemical evolution of patients with sepsis.

Conditions: Sepsis

Summary: triple blind placebo-controlled study to determine if administering citrulline in patients with sepsis and severe sepsis slows progression to multiple organ failure and death, measuring biomarkers of endothelial dysfunction. patients are divided into placebo or citrulline and followed up for 1 month.

consecutive patients with sepsis are being recited from intensive care unite of imss at the cmn siglo xxi and cmn la raza over the period of november 2015 through june 2016. after signing an informed consent they will be randomized into 80 for intervention arm and 80 for the placebo arm. all patients will receive usual medical treatment; and during seven days citurlline arm subjects will receive supplementation with oral or nasogastric citrulline (10 g/day), while other group patients will receive during seven days oral or nasogastric placebo (10 g/day) with no visible difference between these. microalbuminuria and interleukines 1, 6, and 10 will be measured at randomization and at day 7. all subjects will be followed for 28 days, and after the follow-up period results will be analyzed to determine de efficacy and safety of citrulline, primary outcome are the incidence of multiple organic failure and death, also microalbuminuria levels 1,6,10-interleukines. we will use student-t and chi2 for statistical analysis.

Eligibility criteria:
inclusion criteria: * sepsis * severe sepsis * diagnosis of sepsis in the first 36 hours of hospitalization. * informed consent * intestinal tract intact exclusion criteria: * terminal cancer * acute and chronic liver diseases * chronic renal failure. * acute renal failure akin iii. * pregnant and postpartum women * dying patients. * patients with cardiac arrest. * active gastrointestinal bleeding. * steroids or immunosuppressants. * enrolled in another study intervention. * citrulline allergy.

Keywords: sepsis citrulline endothelial toxemia endothelial determination of progression with vs without citrulline
preventive program in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study monitor the immediate and persistent impact of a preventive complex six-month program specifically developed for newly diagnosed people with multiple sclerosis on fatigue, mental and physical fitness, and quality of life. the study determined whether changes in clinical function are related to changes in neurohormones, and whether the effect of therapy is dependent on the active approach of study participants.

the patients who were newly diagnosed with ms underwent a six-month preventive comprehensive program, which included individual physiotherapy focused on the treatment of functional disorders of the loco-motor system and therapy on a neurophysiological basis, group psychotherapy and controlled aerobic training. the participants were examined three times - before the start of the physiotherapy program, immediately after its completion and six months apart. influence on physical fitness (spiroergometric examination), fatigue (modify fatigue impact scale, fatigue scale for motor and cognitive functions), depression (beck scale for evaluation of depression), admission of disease rs (inventory of admission of multiple sclerosis, quality of life) life and selected neurohormones (dehydroepiandrosterone-dhea, dehydroepiandrosterone sulphate - dheas, cortisol).

Eligibility criteria:
inclusion criteria: * definite ms * stable clinical status in the preceding 3 months * imumnomodulatory treatment for at least two years (including glatiramer acetate, interferon beta-1a, 1b, mitoxantrone, fingolimod, natalizumab) * expanded disability status scale (edss)≤6 * predominant motor impartment * six months or more without any physiotherapy * ability to undergo ambulatory physiotherapy exclusion criteria: * other neurological disease or conditions disabling movement

Keywords: preventive program multiple sclerosis rehabilitation
carotid intima-media thickness in japan statin treatment against recurrent stroke(j-stars echo)

Conditions: Ischemic Stroke

Summary: carotid ultrasound can reveal the intima-media complex thickness(imt), that has been reported to be a marker of atherosclerosis as well as a risk of cardiovascular events, and to be attenuated by 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitors (statins) . this substudy of j-stars will observe the temporal profile of carotid imt prospectively in the patients with prescription of pravastatin and the control.


Eligibility criteria:
inclusion criteria: * ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset * hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of statin within previous 30 days * able to visit outpatient department * informed consent on the form. exclusion criteria: * ischemic stroke of other determined cause according to the toast classification * ischemic heart disease and necessary to use statin * hemorrhagic disorders * platelet count \<=100,000/ul within 3 months prior to study start * alanine aminotransferase (alt) or aspartate aminotransferase (ast)\>= 100iu/l within 3 months prior to study start * serum creatinine \>=2.0mg/dl within 3 months prior to study start * a scheduled operation * the presence of malignant disorder * patients whom carotid ultrasound cannot examine because of neck tumor or torticollis * patients after carotid endarterectomy or radiation therapy to neck * patients whose carotid ultrasound cannot be examined because of neck tumor or torticollis * patients after carotid endarterectomy or radiation therapy to neck

Keywords: stroke brain ischemia cerebrovascular accident statin hydroxymethylglutaryl-coa reductase inhibitors cholesterol hypercholesterolemia hyperlipidemia multicenter studies prospective studies endpoint determination randomized controlled trials recurrence pravastatin plaque tunica intima tunica media ultrasonography carotid arteries
mindset intervention for nicotine dependence

Conditions: Psychology, Social; Smoking Cessation; Smoking (Tobacco) Addiction

Summary: this study evaluates a new digitally delivered mindset based intervention in addition to a smartphone application (app) for smoking cessation. participants will be provided an app (smartquit) that teaches them skills to quit, and will be randomly assigned to either receive a growth mindset intervention or to a control group.

want to quit smoking? welcome to the mind study, conducted by researchers at seattle's fred hutchinson cancer research center. join now to get a smartphone app-based quit smoking program that includes: * personalized plans for quitting * help with dealing with urges to smoke * information on nicotine withdrawal * help staying motivated * tracking progress with quitting * a certificate of completion once you complete the program * scientifically-based information on quit medications the mind study gives you all these and more to help you quit smoking and live a happier, healthier life. for more information, visit mind.fredhutch.org.

Eligibility criteria:
inclusion criteria: (1) age 18 or older, (2) smokes at least five cigarettes daily for at least past 12 months, (3) wants to quit in the next 30 days, (4) interested in learning skills to quit smoking, (5) resides in us, (6) has at least daily access to their own smartphone, (7) knows how to login and download a smartphone application from their smartphone, (8) willing and able to read in english, (9) not participating in other smoking cessation interventions (including our other intervention studies). to increase follow-up retention, eligibility criteria also include: (10) willing to complete one follow-up survey, (11) provide email, phone, and mailing address. exclusion criteria: opposite of inclusion.

Keywords: smoking smartphone technology addiction
study of kos-862 (epothilone d) in metastatic prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this trial is to study kos-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

this study is a phase 2, single arm study of kos-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. psa response is the primary end-point and objective responses will be checked as available.

Eligibility criteria:
inclusion criteria: * at least 18 years of age. * metastatic disease. * one previous treatment including docetaxel (taxotere). * at least 3 weeks since last surgery/radiation/chemotherapy * ecog performance status of 0, 1 or 2 exclusion criteria: * active brain metastases

Keywords: prostate
evaluation of the effect of artesunate in friedreich ataxia (fa)

Conditions: Friedreich Ataxia

Summary: this dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of friedreich ataxia. it will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase i-ii open trial


Eligibility criteria:
inclusion criteria: * patients with fa confirmed by genetic analysis * weight of at least 50 kg * compliant patient agreeing to come to all protocol visits * signature of consent form by patient or parents of minor patient * patients with no treatment during 30 days prior to the first intake of study drug, except cardiac, diabetes and spasticity treatments * patients agreeing to use effective contraception for the duration of the study and up to 91 days after the last dose of the study treatment * affiliation to an health insurance scheme of beneficiary of such a scheme exclusion criteria: * patient under justice protection * female patients * abnormal biological values of renal and liver functions and cell blood count (cbc) * progressive associated disease * treatment interfering with iron transport within 30 days before first intake of artesunate * participation to another clinical trial * hypersensitivity to artesunate or to any component of the drug * blood potassium lower than normal value * qt / qtc interval \> 450 ms on the ecg performed at inclusion * congenital long qt syndrome * family history of sudden cardiac death before the age of 50 * heart disease: ischemia or myocardial infarction, congestive heart failure or conduction disorder in the 6 months preceding inclusion * history of arrhythmia * electrolyte imbalances: hypomagnesemia, hypocalcemia * bradycardia (\<50 beats per minute) * acute neurological events within 6 months prior to inclusion
group sessions and web-based treatment targeting children with obesity age 5-12 years and their families

Conditions: Childhood Obesity

Summary: the aim of this study is to assess the efficacy of group sessions and a web-based program for children with obesity age 5-12 years and their parents. the intervention consist of a doctor's appointment, four group-based education sessions over four weeks, psychical activity on prescription and a 12-week web-based treatment program and will be offered to children aged 5-12 years with obesity (international obesity task force-bmi \>30), and their parents.

obesity in children and adolescents worldwide has increased from 1 % in 1975 to about 6 % in 2016. experts have estimated that the world will have more obese children and adolescents than underweight at the year 2022. preventing and reversing excess weight gain in children is important since obesity often tracks into adulthood with adverse health consequences. web-based interventions have been shown to be effective, to have a beneficial treatment outcome and have been proposed to have great potential to reach many children and improve cost effectiveness. this is a randomized controlled study with cross-over design. the intervention consist of a doctor's appointment, four group-based education sessions over four weeks, psychical activity on prescription and a 12-week web-based treatment program. the control group will have standard care treatment consisting of doctor's appointment and, in some cases, contact with dietician.

Eligibility criteria:
inclusion criteria: * obesity according to international obesity task force (iotf) * be able to speak and write swedish * have internet access in parents' home exclusion criteria: * obesity together with other severe disease including neuropsychiatric disorder

Keywords: childhood obesity bmi sds
treatment period and long-term effect of functional electric stimulation (fes) for bruxism

Conditions: Bruxism

Summary: to investigate the effect of the treatment with grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep.


Eligibility criteria:
inclusion criteria: * signed and dated icf * 18 years or older * fulfill the rdc-criteria for myofascial tmd diagnose (group 1a or 1b) * average pain more that 3 on a visual analog scale (vas) in the baseline period exclusion criteria: * contraindication of concommitant diseases for the study judged by investigator * daily use of pain medication, e.g. prophylaxis against migraine or headache. * patients who are using occlusal splints in the treatment period.

Keywords: bruxism emg biofeedback
effect of l-ornithine-l-aspertate (lola) on the gut microbiome

Conditions: Cirrhosis

Summary: study to test the effect of the drug "l-ornithine.l-aspertate" (lola) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

liver cirrhosis is associated with gut microbiome dysbiosis, which may drive intestinal inflammation, gut barrier dysfunction and the development of complications. lola is a well-established drug against elevated ammonia levels that contribute to hepatic encephalopathy and sarcopenia. in a recent retrospective study, lola has been shown to improve gut microbiome dysbiosis. in this study we aim to investigate whether lola therapy over three months in patients with liver cirrhosis (irrespective of the etiology) and covert or overt hepatic encephalopathy (he) leads to an improvement in gut microbiome dysbiosis, as well as markers of gut permeability, inflammation, muscle function and ammonia levels.

Eligibility criteria:
inclusion criteria: * • liver cirrhosis (clinical/radiological/histological diagnosis) * indication for lola use (covert or over hepatic encephalopathy, grad 0-2)) * written informed consent * age 18 -100 years exclusion criteria: * • allergy to lola or its constituents, or to medications with a similar chemical structure (oral nutritional supplements are allowed when stable \>/= 8 weeks before and during the study) * recent (\</= 8 weeks) changes of the dose of the lactulose therapy for hepatic encephalopathy * rifaximin or any other antibiotic therapy within the past 4 weeks * intake of lola in the past four weeks before inclusion * intake of l-dopamine * renal insufficiency with a serum creatinine \>3mg/dl * hepatocellular carcinoma bclc d under best supportive care * inability to give informed consent * pregnancy or breastfeeding * participation in another interventional trial within the last 30 days